-
Monomethyl auristatin E (MMAE) is a
synthetic antineoplastic agent.
Because of its toxicity, it
cannot be used as a drug itself; instead, it is linked...
-
Monomethyl auristatin is any of a
group of
synthetic antineoplastic agents derived from the sea slug
Dolabella auricularia:
Monomethyl auristatin E Monomethyl...
-
Monomethyl auristatin F (MMAF) is a
synthetic antineoplastic agent. It is part of the
approved drug
belantamab mafodotin in
multiple myeloma and some experimental...
-
spacers to
three to five
units of the
antimitotic agent monomethyl auristatin E (MMAE,
reflected by the 'vedotin' in the drug's name). The peptide-based...
- tisotumab, a
monoclonal antibody against tissue factor, and
monomethyl auristatin E (MMAE), a
potent inhibitor of cell division. It is
administered by infusion...
-
Payloads include the
microtubulin inhibitors monomethyl auristatin A MMAE,
monomethyl auristatin F MMAF and mertansine, DNA
binder calicheamicin and topoisomerase...
-
Oxford BioTherapeutics Ltd.
Seattle Genetics'
proprietary monomethyl auristatin E or MMAE-based antibody-drug
conjugate technology, emplo**** in brentuximab...
-
Brentuximab Vedotin (SGN-35)
Adcetris Mollusk Antibody-Drug
Conjugate (MM
Auristatin E) CD30 and
Microtubules 9/19
Cancer Plitidepsin Aplidin Tunicate Depsipeptide...
-
antibody (depatuxizumab)
conjugated to the
tubulin inhibitor monomethyl auristatin F via a
stable maleimidocaproyl link. This drug was
developed by AbbVie...
- (BCMA)
conjugated with a
cytotoxic agent,
maleimidocaproyl monomethyl auristatin F (mcMMAF). The antibody-drug
conjugate binds to BCMA on
myeloma cell...
